Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autoimmune Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    526 result(s) found for: Autoimmune Diseases. Displaying page 12 of 27.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    EudraCT Number: 2008-003005-14 Sponsor Protocol Number: GVHD 1 Start Date*: 2010-12-30
    Sponsor Name:ASSOCIAZIONE MALATTIE SANGUE
    Full Title: Antimicotyc prophylaxis with Amphotericina B in lypidic complex aerosol in GVHD patients under steroid treatment
    Medical condition: GVHD patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018799 GVHD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001508-19 Sponsor Protocol Number: IMA-GVH Start Date*: 2007-09-06
    Sponsor Name:AZIENDA OSPEDALIERA S. CARLO
    Full Title: TRATTAMENTO CON IMATINIB MESILATO DELLA GVH CRONICA SEVERA SCLERODERMA-LIKE REFRATTARIA ALLA TERAPIA IMMUNOSOPRESSIVA CONVENZIONALE
    Medical condition: GVH CRONICA ESTESA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004067-53 Sponsor Protocol Number: Thymo-06 Start Date*: 2006-09-05
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: A multicenter randomized study on the use of rabbit anti-T-Lymphocite globulin ATG different doses to prevent GVHD in children receiving allogenic stem cell transplantation
    Medical condition: ematological malignant neoplasm
    Disease: Version SOC Term Classification Code Term Level
    6.1 10018651 PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001892-12 Sponsor Protocol Number: 00557 Start Date*: 2007-10-15
    Sponsor Name:University Medical Centre Freiburg
    Full Title: Everolimus and mycophenolate as GvHD-prophylaxis in the allogenous blood stem cell transplantation (Everolimus und Mycophenolsäure als GvHD-Prophylaxe in der allogenen Blutstammzelltransplantation)
    Medical condition: Prophylaxis of graft-versus-host disease after allogenous blood stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018799 GVHD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005809-21 Sponsor Protocol Number: ADN-GVHD vs BT 5/9 Start Date*: 2008-06-06
    Sponsor Name:FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO
    Full Title: Treatment of Steroid refractory Graft versus Host Disease with monoclonal antibody B T 5/9 (anti-CD26)
    Medical condition: patients with acute GVHD not responsive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023279-25 Sponsor Protocol Number: AloVita Start Date*: 2011-02-24
    Sponsor Name:José Antonio Pérez Simón
    Full Title: Efecto inmunomodulador de la vitamina D postrasplante alogénico: Ensayo clínico fase I-II multicéntrico
    Medical condition: Enfermedad Injerto contra Hésped en trasplante alogénico de médula ósea.
    Disease: Version SOC Term Classification Code Term Level
    13 10018651 Enfermedad del injerto contra el huésped LLT
    13 10059041 Trasplante alogénico periférico de células madre hematopoyéticas LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001849-13 Sponsor Protocol Number: 2013/cardio3 Start Date*: 2013-07-09
    Sponsor Name:ASLTO2-Maria Vittoria Hospital Cardiology
    Full Title: AnakInRa Treatment of Recurrent Idiopathic Pericarditis
    Medical condition: idiopathic recurrent pericarditis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000101-11 Sponsor Protocol Number: ProfGVHD Start Date*: 2008-04-02
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Multicenter, prospective, randomized clinical trial to assess two different doses of anti-human-T-lymphocyte immune serum preparation derived from rabbit in GVHD profilaxis in pediatric population ...
    Medical condition: graft versus host disease profilactic use
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018653 Graft-versus-host disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005019-81 Sponsor Protocol Number: INO-0106 Start Date*: 2006-12-22
    Sponsor Name:OPi
    Full Title: A European Open-Label, Multicentre, Phase II Study of Inolimomab in the Treatment of Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation...
    Medical condition: For treatment of patients with Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation for Hematological Malignancies in Adult patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018651 Graft versus host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003451-11 Sponsor Protocol Number: TP0006 Start Date*: 2020-04-30
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chroni...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) DK (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-004304-19 Sponsor Protocol Number: 117119 Start Date*: 2015-07-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary v...
    Medical condition: Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by Haemophilus influenzae type B (...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000164-24 Sponsor Protocol Number: 109836 Start Date*: 2007-05-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, partially-blind, randomized multicentre study to assess the safety and immunogenicity of an HPV-16/18/33/58 L1 VLP vaccine formulated with different adjuvant systems when administered...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004616-12 Sponsor Protocol Number: CCDZ173X2203 Start Date*: 2016-05-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome
    Medical condition: Primary Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004063-36 Sponsor Protocol Number: CELIM-RCD-002 Start Date*: 2016-02-22
    Sponsor Name:Celimmune LLC
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Type II Refractory Celiac Disease, an In Situ Sm...
    Medical condition: Type II Refractory Celiac Disease (RCD-II)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001770-59 Sponsor Protocol Number: BAT-2306-002-CR Start Date*: 2022-10-19
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 with Cosentyx® in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002542-38 Sponsor Protocol Number: CAEB071A2210 Start Date*: 2007-11-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis.
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001107-12 Sponsor Protocol Number: GESIDA7011 Start Date*: 2011-07-15
    Sponsor Name:Fundación SEIMC-GESIDA
    Full Title: Ensayo Clínico aleatorizado, abierto, de no inferioridad y con seguimiento a 96 semanas sobre la eficacia de azatanavir / ritonavir + lamivudina como tratamiento de mantenimiento en pacientes con ...
    Medical condition: Infección crónica por el VIH-1.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10001509 AIDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002362-66 Sponsor Protocol Number: 111738 Start Date*: 2008-09-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, observer-blind, multi-country, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals FLU NG vaccine compared to the referenc...
    Medical condition: Immunization against influenza in male and female subjects aged 66 years or older and 19-43 years of age.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003896-41 Sponsor Protocol Number: D5181C00001 Start Date*: 2015-03-27
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren’s Syndrome
    Medical condition: Primary Sjogren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002437-13 Sponsor Protocol Number: TMC114-C226 Start Date*: 2006-05-09
    Sponsor Name:Tibotec Pharmaceuticals Ltd.
    Full Title: Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options.
    Medical condition: HIV-1 infected patient
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:48:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA